JOINT VENTURE FOR DEVELOPMENT OF APO E MIMETIC PEPTIDE MOLECULE AEM-28 AND ANALOGS (Details Textual) - USD ($)
|
|
6 Months Ended |
35 Months Ended |
Aug. 03, 2012 |
Jun. 30, 2015 |
Jun. 30, 2015 |
| Related Party Transaction [Line Items] |
|
|
|
| Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures |
$ 6,000,000
|
$ 6,000,000
|
$ 6,000,000
|
| Joint Venture Investments In Voting Common Ownership Units (in shares) |
600,000
|
|
|
| Joint Venture Method Investment Ownership Percentage |
60.00%
|
|
|
| Joint Venture Investments In Non Voting Preferred Ownership Units |
5,000,000
|
|
|
| Joint Venture Investments Common Ownership Units, Co-venture (in shares) |
400,000
|
|
|
| Ownership Percentage Co-venture |
40.00%
|
|
|
| Percentage Of Royalty Payment |
3.00%
|
|
|
| Development Activities Monthly Fee |
$ 63,000
|
|
|
| Accounting and Administrative Monthly Fee |
$ 1,000
|
|
|
| Joint Venture, Operating Expenses, Inter Company Transactions |
|
351,000
|
6,586,000
|
| Joint Venture, Operating Expenses Allocated To Company |
|
351,000
|
5,919,000
|
| Percentage Of Non Royalty Income |
5.00%
|
|
|
| Reduced Monthly Management Fee |
$ 35,000
|
|
|
| Revolving Credit Facility [Member] |
|
|
|
| Related Party Transaction [Line Items] |
|
|
|
| Line of Credit Facility, Maximum Borrowing Capacity |
|
700,000
|
700,000
|
| Long-term Line of Credit |
|
739,000
|
739,000
|
| Common Stock [Member] |
|
|
|
| Related Party Transaction [Line Items] |
|
|
|
| Joint Venture Losses Recognition Criteria, Common Ownership Equity |
|
$ 0
|
$ 0
|
| Noncontrolling Interest, Ownership Percentage by Parent |
|
60.00%
|
60.00%
|
| Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners |
|
40.00%
|
40.00%
|
| Preferred Stock [Member] |
|
|
|
| Related Party Transaction [Line Items] |
|
|
|
| Noncontrolling Interest, Ownership Percentage by Parent |
|
100.00%
|
100.00%
|
| Noncontrolling Interest [Member] |
|
|
|
| Related Party Transaction [Line Items] |
|
|
|
| Noncash or Part Noncash Acquisition, Other Liabilities Assumed |
|
|
$ 667,000
|
| Subsequent Event [Member] | Revolving Credit Facility [Member] |
|
|
|
| Related Party Transaction [Line Items] |
|
|
|
| Line of Credit Facility, Maximum Borrowing Capacity |
|
$ 700,000
|
$ 700,000
|
| Exclusive License Agreement [Member] |
|
|
|
| Related Party Transaction [Line Items] |
|
|
|
| Annual Maintenance Payments |
25,000
|
|
|
| Exclusive License Agreement [Member] | Maximum [Member] |
|
|
|
| Related Party Transaction [Line Items] |
|
|
|
| Milestone Payments |
500,000
|
|
|
| Royalty Expense |
1,000,000
|
|
|
| Exclusive License Agreement [Member] | Minimum [Member] |
|
|
|
| Related Party Transaction [Line Items] |
|
|
|
| Milestone Payments |
50,000
|
|
|
| Royalty Expense |
500,000
|
|
|
| Lipimetix [Member] |
|
|
|
| Related Party Transaction [Line Items] |
|
|
|
| Noncash or Part Noncash Acquisition, Other Liabilities Assumed |
|
667,000
|
|
| Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed), Total |
378,000
|
$ 378,000
|
|
| Voting Common Ownership Units [Member] |
|
|
|
| Related Party Transaction [Line Items] |
|
|
|
| Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures |
1,000,000
|
|
|
| Non Voting Preferred Ownership Units [Member] |
|
|
|
| Related Party Transaction [Line Items] |
|
|
|
| Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures |
$ 5,000,000
|
|
|